Staidson and J&J’s Teclistamab Gain Breakthrough Designation for Hemophilia and Myeloma
The Center for Drug Evaluation (CDE) has indicated that Staidson (Beijing) Pharmaceutical Co., Ltd’s (SHE:...
Drug
InnoCare Pharma and CStone Pharmaceuticals’ Drugs Receive Prioritized CDE Review
The Center for Drug Evaluation (CDE) has granted prioritized review status to InnoCare Pharma’s (HKG:...
Biocytogen and Tracon Pharmaceuticals Gain FDA IND Approval for Sarcoma Trial
China-based Biocytogen (Beijing) Co., Ltd and US-based Tracon Pharmaceuticals Inc. (Nasdaq: TCON) announced that the...
Hengrui Medicine’s Dalpiciclib Hits Superiority Criteria in Phase III Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its Phase III SHR6390-III-302 study...
ImmuneOnco’s IMM40H Receives NMPA Clinical Trial Approval for CD70 Antibody
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced that it has received clinical trial approval from the...
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II...
Henlius Biotech’s PD-1 Inhibitor Serplulimab Secures NMPA Review for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the National Medical Products Administration (NMPA) has...
Junshi Biosciences’ TAB009/JS009 and JS110 Advance in Cancer Trials
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study
Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...
Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...
Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases
Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...
Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial
Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...
Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers
Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...
CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...
SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial
Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...
Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors
Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...
BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...
Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...
Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case
China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...